TD Cowen Maintains a Buy Rating on Boston Scientific (BSX)

Boston Scientific Corporation (NYSE:BSX) is one of the Stocks Expected to Bounce Back According to Analysts. The stock has fallen more than 52% year-to-date, but the Street expects more than 65% upside from the current level.

​Recently, on June 16, TD Cowen analyst Josh Jennings maintained his Buy rating on Boston Scientific Corporation (NYSE:BSX) with a price target of $61. The analyst noted that the firm remains confident in the company’s resilience despite some near-term pressures.

​The analyst believes that Boston Scientific can meet the lower end of its fiscal Q2 2026 revenue and EPS guidance. Moreover, the analysts noted that the expectations for the earnings have drifted down recently, which makes them increasingly achievable. He acknowledges that certain areas have underperformed, particularly the US Watchman sales and a handful of other franchises. However, he remains bullish overall, as management continues to expect total organic growth to land within its targeted ranges for both Q2 and the full year 2026.

Boston Scientific Corporation (NYSE:BSX) is a healthcare company,  incorporated in 1979, that specializes in medical devices for interventional medical specialties. The company’s segments include MedSurg and Cardiovascular.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.